Do anticholinergic medications increase the risk of long-term cognitive decline and dementia? In this podcast, we will review the latest research examining the relationship between anticholinergic medication use and cognitive decline.

Dr. Tammas Kelly shares tips on high dose thyroid in treatment-resistant bipolar depression.

ADHD is one of the most treatable conditions in psychiatry if patients adhere to medication regimens. So, why are parents so resistant to stimulant medications and how can we approach these misconceptions?

A recent paper lists 5 therapies for treatment-resistant depression, but the research keeps rolling in, and we bring you 2 more to add to the list.

We often hear about the “Tarasoff warning” and the “duty to protect,” but what do these mean, and who was Tarasoff? In today’s episode, we’ll break down the Tarasoff rulings and how you can navigate the legal ambiguities surrounding our duty to protect. 

Zuranolone is a neurosteroid that is inching its way toward FDA approval in depression. In some ways it’s similar to brexanolone (Zulresso) – the IV therapy approved in 2019 for postpartum depression – and in other ways it’s different.

Borderline personality disorder can be complicated to treat, especially in frantic and high stress settings like the emergency department or inpatient psychiatric unit. In today’s episode, we’ll address the best practices for managing patients with borderline personality disorder in emergency settings.

Naloxone saves lives, and it’s critical that we get naloxone into the hands of as many people as we can. In this podcast, Dr. Phillip Coffin and I will discuss the risk factors associated with opioid overdose, the different naloxone formulations, who should be prescribed naloxone, and how we as clinicians can promote the availability of naloxone in our communities. 

Margaret Chisolm, MD, shares a model of flourishing that moves beyond symptomatic treatment and helps patients find meaningful lives even when their medications do not work.